Checkmate Pharmaceuticals (CMPI) Peer Comparison

$10.50

$0.00 (0.00%)

As on 09-Jun-2022 09:30EDT

Market cap

$231 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.2

Div. Yield

0 %

Edit

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Market cap ($ Mln)	231	27,916
Revenue ($ Mln)	--	5,807
Net Profit ($ Mln)	-63.14	589.47
Net Margin (%)	-332,336.84	10.17
RoE (%)	-92.50	15.22
Price to Earnings	--	48.06
Price-To-Book	4.19	7.07

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Operating Revenue	0.00	5,806.85
Cost of Revenue	0.00	1,014.21
Gross Profit	--	4,763.81
Operating Expenses	63.18	4,050.44
Operating Profit (EBIT)	-63.18	742.20
Other Income	0.02	-10.00
Profit before Tax	-63.14	732.21
Provision for Tax	0.00	142.73
Profit after Tax (Net Income)	-63.14	589.47
Minority Interest	0.00	0.00
Consolidated Profit	-63.14	413.85

Liabilities ($ Mln)

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Shareholder's Funds	55.00	3,908.52
Minority Interest	0.00	0.00
Non-Current Liabilities	0.00	2,086.84
Current Liabilities	11.94	1,378.87
Total Liabilities	78.84	7,434.16

Assets ($ Mln)

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Non-Current Assets	4.83	4,906.37
Current Assets	62.11	2,467.86
Total Assets	78.84	7,434.16
Total Debt*	0.00	1,611.30
Net Current Assets	50.17	1,088.99

Cashflow ($ Mln)

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Cash From Operating Activities	-53.72	1,771.68
Cash Flow from Investing Activities	61.19	-729.83
Cash from Financing Activities	0.15	-1,054.85
Net Cash Inflow / Outflow	--	-25.77

Ratios

Profitability Ratios

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
ROCE (%)	-63.09	9.61
ROE (%)	-92.50	15.22
ROA (%)	-61.33	6.50
EBIT Margin (%)	--	12.61
Net Margin (%)	-332,336.84	10.17
Cash Profit Margin (%)	--	0.00

Growth Ratios

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Revenue Growth (%)	--	5.93
EBIT Growth (%)	-44.48	-28.69
Net Profit Growth (%)	-46.05	-26.79
EPS Growth (%)	73.39	-24.53
Book Value Growth (%)	-51.06	-5.69

Valuation Ratios

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Price / Earnings	-1.03	50.31
Price / Book Value	0.91	7.60
Dividend Yield (%)	--	--
EV/EBITDA	0.13	19.80
Market Cap ($ Cr)	--	--

Solvency Ratios

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Debt to Equity	0.00	0.41
Short term debt to equity ratio	0.00	0.00
Current Ratio	5.20	1.79
Quick Ratio	5.20	1.77
Interest Coverage	-3,322.37	17.09

Operating Efficiency Ratios

	Checkmate Pharmaceuticals (CMPI)	Cerner (CERN)
Debtors to sales (%)	--	20.29
Asset Turnover	0.00	0.64
Receivable days	--	73.81
Inventory Days	--	9.34
Payable days	--	103.14
Cash Conversion Cycle	--	-19.99

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly